Recombinant Human TNFRSF5 Protein，His

TNFRSF5, also known as CD40, is a member of the tumor necrosis factor receptor superfamily, playing a crucial role in immune responses, B cell activation, and T cell interactions. It is predominantly expressed on antigen-presenting cells, including B cells, dendritic cells, and macrophages, where its engagement with the ligand CD40L (CD154) triggers a series of intracellular signaling pathways that promote cell survival, proliferation, and differentiation. The significance of TNFRSF5 in both adaptive immunity and immunological disorders such as autoimmune diseases and cancers has generated substantial interest in the development of recombinant CD40 proteins for therapeutic applications. Research has shown that manipulating CD40-CD40L interactions can enhance immune responses in vaccine development, promote antitumor effects, and modulate the immune microenvironment. Additionally, the study of TNFRSF5 recombinant proteins provides insights into its structure-function relationship, aiding in the design of targeted therapies that can improve immune system targeting of malignancies. Given the potential of CD40 as a therapeutic target, ongoing investigations focus on optimizing its recombinant forms for clinical applications, elucidating the mechanisms underlying its signaling pathways, and exploring its potential in combination therapies to enhance anti-tumor immunity and overcome immune evasion strategies employed by cancer cells.